Literature DB >> 28105108

Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma.

Liang Wang1, Hongwei Gao1, Ningji Gong2, Mingzhi Gong1.   

Abstract

The present study aimed to investigate the effects of microRNA (miRNA/miR)-497 expression levels on the expression levels of synuclein γ (SNCG) in serum samples, as well as osteosarcoma and lung-metastatic tissue samples, from patients with osteosarcoma. Between December 2010 and August 2013, fasting peripheral blood was collected from 36 patients with osteosarcoma for serum separation. In addition, osteosarcoma and lung metastatic tissues were resected from 15 osteosarcoma patients with lung metastasis by surgery. Bioinformatics was employed to predict the amount miRNA that binds to SNCG. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression levels of SNCG and miR-497, and western blotting was performed to determine protein expression levels. It was observed that SNCG mRNA and protein expression levels were significantly upregulated in osteosarcoma tissues (P<0.01). Additionally, SNCG mRNA (P<0.01) and protein (P<0.05) expression levels were significantly upregulated in the blood of patients with osteosarcoma. SNCG mRNA and protein expression levels were also significantly upregulated in lung metastatic tissues (P<0.01). miR-497 was significantly downregulated in all three samples; therefore downregulation of miR-497 may lead to the occurrence, development and metastasis of osteosarcoma through the upregulation of SNCG mRNA. In summary, the upregulation of SNCG in blood, osteosarcoma tissue and lung metastatic tissue samples is associated with the dowregulation of miR-497, suggesting that miR-497 may be a potential marker and therapeutic target for the treatment of osteosarcoma.

Entities:  

Keywords:  lung metastasis; microRNA-497; osteosarcoma; synuclein γ

Year:  2016        PMID: 28105108      PMCID: PMC5228581          DOI: 10.3892/etm.2016.3838

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

Review 1.  [Synucleins--to have or not to have].

Authors:  N N Ninkina; V L Bukhman
Journal:  Genetika       Date:  2000-11

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing.

Authors:  H Ji; Y E Liu; T Jia; M Wang; J Liu; G Xiao; B K Joseph; C Rosen; Y E Shi
Journal:  Cancer Res       Date:  1997-02-15       Impact factor: 12.701

Review 4.  Primary malignant bone tumors--recent developments.

Authors:  Meera Hameed; Howard Dorfman
Journal:  Semin Diagn Pathol       Date:  2011-02       Impact factor: 3.464

Review 5.  Osteosarcoma: review of the past, impact on the future. The American experience.

Authors:  Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

Review 6.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.

Authors:  Wei Wang; Fang Ren; Qinghua Wu; Dazhi Jiang; Hongjun Li; Huirong Shi
Journal:  Oncol Rep       Date:  2014-08-22       Impact factor: 3.906

8.  MiRNA-15a mediates cell cycle arrest and potentiates apoptosis in breast cancer cells by targeting synuclein-γ.

Authors:  Ping Li; Xiao-Bing Xie; Qian Chen; Guo-Lian Pang; Wan Luo; Jian-Cheng Tu; Fang Zheng; Song-Mei Liu; Lu Han; Jian-Kun Zhang; Xian-Yong Luo; Xin Zhou
Journal:  Asian Pac J Cancer Prev       Date:  2014

9.  Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.

Authors:  Jacqueline Morgan; Anna V Hoekstra; Eloise Chapman-Davis; Jennifer L Hardt; J Julie Kim; Barbara M Buttin
Journal:  Gynecol Oncol       Date:  2009-05-24       Impact factor: 5.482

10.  MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.

Authors:  S T Guo; C C Jiang; G P Wang; Y P Li; C Y Wang; X Y Guo; R H Yang; Y Feng; F H Wang; H-Y Tseng; R F Thorne; L Jin; X D Zhang
Journal:  Oncogene       Date:  2012-06-18       Impact factor: 9.867

View more
  3 in total

1.  SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.

Authors:  Jing Zhang; Xiao-Han Liu; Cong Li; Xiao-Xing Wu; Yan-Lin Chen; Wen-Wen Li; Xian Li; Fan Gong; Qin Tang; Dan Jiang
Journal:  J Exp Clin Cancer Res       Date:  2020-05-07

Review 2.  Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

Authors:  Lavinia Raimondi; Angela De Luca; Viviana Costa; Nicola Amodio; Valeria Carina; Daniele Bellavia; Pierfrancesco Tassone; Stefania Pagani; Milena Fini; Riccardo Alessandro; Gianluca Giavaresi
Journal:  Oncotarget       Date:  2017-08-03

Review 3.  Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.

Authors:  Hao Wang; Ran Peng; Junjie Wang; Zelian Qin; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2018-04-23       Impact factor: 6.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.